Interní Med. 2005; 7(10): 444-446

SOLITARY PLASMACYTOMA

MUDr. Jaroslav Bačovský CSc
III. interní klinika FN a LF UP Olomouc

Solitary plasmacytomas are localized malignant tumors arising by local proliferation of plasma cell. They rare and amount to 3 to 5% of all malignant plasmacytoma disorders. The most important feature for the examination of solitary plasmacytoma is a sure diagnosis of the really solitary lesion, because its therapeutic modality differs from that of a generalized disease. Solitary extramedullary plasmacytoma usually displays a local expansive character but show a low tendency to generalization. Solitary extramedullary plasmacytoma occur in the nasopharynx, oropharynx, tonsils, nasal cavity and paranasal sinuses, very rarely in the nodes, subcutis, pleura and testis. Local radiotherapy may lead to a complete cure. Solitary plasmacytoma of bone is more frequent than solitary extramedullary plasmacytoma. Its prognosis is less favorable. There is a high risk of development from solitary plasmacytoma of bone into multiple myeloma in contrast to solitary extramedullary plasmacytoma. It should be examined carefully whether a case is solitary plasmocytoma of bone or multiple myeloma. Solitary plasmacytoma of bone frequently incline to generalization in contrast to solitary extramedullary plasmacytoma. Therapeutic modality depends on clinical manifestations. Treatment of choice is radiotherapy with curative dose of 40–50 GY. The irradiation site is larger that the original size of tumor. Surgery is indicated in case of acute spinal compresion or probatory extirpation of tumor. Chemotherapy is indicated if monoclonal immunoglobulin persists in the serum or urine.

Keywords: Key words: solitary extramedullary plasmacytoma, solitary plasmacytoma of bone.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bačovský J. SOLITARY PLASMACYTOMA. Interní Med. 2005;7(10):444-446.
Download citation

References

  1. Aalto Y, Nordling S, Kivioja AH, et al. Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma. Genes Chromosomes Cancer 1999 Jun; 25 (2): 104-107. Go to original source...
  2. Aviles A, Huerta-Guzman J, Delgado S, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 1996; 14: 111-117. Go to original source... Go to PubMed...
  3. Bartl R, Frisch B, Burkhardt R, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol 1982; 51: 361-375. Go to original source... Go to PubMed...
  4. Bataille R, Sany J. Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer 1981; 48: 845-851. Go to original source...
  5. Bradwell AR. Serum free light chain assays. Binding site ltd,2003, ISBN:070424037.
  6. Brinch L, Hahnisdal E, Abrahamsen AF et al. Extramedullary plasmacytomas and solitary plasma cell tumors of bone. Eur J Haemato1 1990; 44: 132-135. Go to original source... Go to PubMed...
  7. Corwin J, Lindberg RD. Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer 1979; 43: 1007-1013. Go to original source...
  8. Dimopoulos MA, Goldstein J, Fuller L et al. Curability of solitary bone plasmacytoma. J Clin Onco1 1992; 10: 587-590. Go to original source... Go to PubMed...
  9. Dimopoulos MA, Moulopulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000; 96: 2037-2044. Go to original source...
  10. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol 1988 Nov; 5(4): 346-364. Go to original source...
  11. Galieni P, Cavo M, Avvisati G, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol 1995; 6: 687-691. Go to original source... Go to PubMed...
  12. Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica 2000 Jan; 85 (1): 47-51.
  13. Ganjoo RK, Malpas JS. Plasmacytoma. In: Myeloma: Biology and Management,2nd edn Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Oxford: Oxford University Press, 1998: 545-558.
  14. Guida M, Casamassima A, Abbate I, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different nosological entities? Tumori 1994; 80: 370-377. Go to original source... Go to PubMed...
  15. Hussong JW, Perkins SL, Schnitzer B, et al. Extramedullary plasmacytoma. A form of marginal zone cell lymphoma? Am J Clin Pathol 1999 Jan; 111 (1): 111-116. Go to original source... Go to PubMed...
  16. Jackson A, Scarffe JH. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone. Eur J Cancer 1990; 26: 363-371. Go to original source... Go to PubMed...
  17. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Onco 1983; 1: 255-262. Go to original source... Go to PubMed...
  18. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 71-87. Go to original source... Go to PubMed...
  19. Liebross RH, Ha CS, Cox JD, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 1063-1067. Go to original source... Go to PubMed...
  20. Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds). Oxford: Oxford University Press, 1998: 545-558.
  21. McLain RF, Weinstein JN. Solitary plasmacytomas of the spine: a review of 84 cases. J Spinal Disord 1989 Jun; 2 (2): 69-74. Go to original source...
  22. Meis JM, Butler JJ, Osbome BM, Ordonez NG. Solitary plasmacytomas of bone and extramedullary plasmacytomas. A clinicopathologic and immunohistochemical study. Cancor 1987; 59: 1475-1485. Go to original source...
  23. Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer 1980; 45: 647-652. Go to original source...
  24. Moulopoulos LA, Dimopoulos MA, Weber D, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993; 11: 1311-1315. Go to original source... Go to PubMed...
  25. Mehta J, Naparstek E, et al. Successful T celldepleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas. Bone Marrow Transplant 1992; 10: 381-382. Go to PubMed...
  26. Poor MM, Hitchon PW, Riggs CE Jr. Solitary spinal plasmacytomas: management and outcome. J Spinal Disord 1988; 1: 295-300. Go to original source... Go to PubMed...
  27. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571. Go to original source... Go to PubMed...
  28. Ščudla V, Minařík J, Schneiderka P, et al.: Význam hodnocení sérových hladin volných lehkých řetězců u mnohočetného myelomu a vybraných monoklonálních gamapatií - první zkušenosti. Vnitř. lék. 2005 (v tisku).
  29. Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) 1976 May; 55(3): 217-238. Go to original source... Go to PubMed...
  30. Woodruff RK, Whittle JM, Malpas JS. Solitary plasmacytoma. I: Extramedullary soft tissue plasmacytoma. Cancer 1979; 43: 2340-2343. Go to original source...
  31. Woodruff RK, Malpas JS, White PE. Solitary plasmacytoma. II: Solitary plasmacytoma of bone. Cancer 1979; 43: 2344-2347. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.